Adamis Pharmaceuticals Corporation (ADMP)

NASDAQ: ADMP · IEX Real-Time Price · USD
0.252
-0.019 (-6.85%)
Sep 27, 2022 10:41 AM EDT - Market open
-6.85%
Market Cap 37.72M
Revenue (ttm) 794,888
Net Income (ttm) -39.89M
Shares Out 149.98M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 172,724
Open 0.262
Previous Close 0.270
Day's Range 0.232 - 0.270
52-Week Range 0.180 - 1.480
Beta 1.04
Analysts Sell
Price Target 0.43 (+71.0%)
Earnings Date Aug 10, 2022

About ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC... [Read more...]

Industry Pharmaceuticals
CEO Dennis Carlo
Employees 15
Stock Exchange NASDAQ
Ticker Symbol ADMP
Full Company Profile

Financial Performance

In 2021, ADMP's revenue was $2.21 million, a decrease of -20.45% compared to the previous year's $2.78 million. Losses were -$45.83 million, -7.21% less than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ADMP stock is "Sell." The 12-month stock price forecast is 0.43, which is an increase of 70.97% from the latest price.

Price Target
$0.43
(70.97% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effe...

6 days ago - GlobeNewsWire

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects

2 weeks ago - GlobeNewsWire

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022

1 month ago - GlobeNewsWire

Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET

1 month ago - GlobeNewsWire

Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose...

1 month ago - GlobeNewsWire

Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals' Stockholders Vote FOR Critical Proposa...

ISS Recommends Stockholders Support Key Proposals  Pertaining to a Reverse Stock Split and New Equity Incentive Plan

1 month ago - GlobeNewsWire

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Interim DSMB review expected in late September Interim DSMB review expected in late September

1 month ago - GlobeNewsWire

Adamis Pharmaceuticals Issues Letter to Stockholders

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose...

2 months ago - GlobeNewsWire

What Makes Adamis (ADMP) a New Buy Stock

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Adamis Appoints Vickie Reed to Board of Directors

New Director Named with Significant Executive Management and Financial Leadership Experience New Director Named with Significant Executive Management and Financial Leadership Experience

4 months ago - GlobeNewsWire

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO

4 months ago - GlobeNewsWire

Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

4 months ago - GlobeNewsWire

Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose,...

4 months ago - GlobeNewsWire

5 Winning Stocks to Land on the Overlooked Rising P/E Trick

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols: GIIIPOOLSHOO
4 months ago - Zacks Investment Research

Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

5 months ago - GlobeNewsWire

US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product

High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths

5 months ago - GlobeNewsWire

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdos...

6 months ago - GlobeNewsWire

Adamis Pharma Recalls Allergy Treatment Symjepi For Potential Manufacturing Defect

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) voluntarily recalls certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level.  The batch...

6 months ago - Benzinga

Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model

Tempol Reduced Lung Inflammation After High Dose Challenge Tempol Reduced Lung Inflammation After High Dose Challenge

6 months ago - GlobeNewsWire

Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potenti...

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 ...

6 months ago - GlobeNewsWire

Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.

6 months ago - GlobeNewsWire

Adamis Pharmaceuticals' Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue

6 months ago - GlobeNewsWire

Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in vari...

7 months ago - GlobeNewsWire

Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company's ongoing Phase 2/3 stud...

7 months ago - GlobeNewsWire

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) f...

8 months ago - GlobeNewsWire